This update discusses the efficacy of narrowband UVB for skin conditions and its integration with modern therapies.
This document updates the scientific evidence and clinical practice regarding narrowband UVB phototherapy (NB-UVB) in dermatology. The review addresses indications, therapeutic regimens, safety aspects, combinations with systemic and biologic agents, and adaptation to special populations. NB-UVB remains a first-line therapy for psoriasis, vitiligo, atopic dermatitis, early mycosis fungoides, and photodermatoses due to its efficacy, safety, and cost-effectiveness. Emerging evidence supports its integration with next-generation systemic therapies. This update provides recommendations for its application in the era of targeted therapies, with an emphasis on efficiency and patient-centered care.
No takes yet. Share an insight, caveat, or question.
Carrascosa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: